Literature DB >> 23006950

Should patients with aggressive peripheral T-cell lymphoma all be treated the same?: no... well yes, ...but maybe not for long.

Alison J Moskowitz1, Matthew A Lunning, Steven M Horwitz.   

Abstract

The peripheral T-cell lymphomas represent about 15% to 20% of non-Hodgkin lymphomas and are marked by clinical and pathologic heterogeneity. The most common T-cell entities include peripheral T-cell lymphoma, not otherwise specified, angioimmunoblastic T-cell lymphoma, and anaplastic large cell lymphoma anaplastic lymphoma kinase-negative, which account for approximately 60% of T-cell lymphoma cases. Because of the rarity of T-cell lymphomas and lack of randomized prospective studies, treatment for these diseases is not well defined. Current treatment strategies draw from data from phase II studies, retrospective analyses, and personal experience. For fit patients who can tolerate treatment with curative intent, we treat peripheral T-cell lymphoma, not otherwise specified, angioimmunoblastic T-cell lymphoma, and anaplastic large cell lymphoma anaplastic lymphoma kinase-negative similarly with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-based induction therapy followed by consolidation with autologous stem cell transplant. Given the marked differences in histology, biology, and clinical presentation for these diseases, it is likely that they should be approached differently. Furthermore, prognostic factors and degree of chemosensitivity as measured by FDG-PET (fluorodeoxyglucose positron emission tomography) should likely be used to guide patients along different treatment pathways. We have a long way to go toward perfecting the treatment for T-cell lymphoma. We believe that a uniform treatment approach for patients with aggressive T-cell lymphoma is not appropriate; however, we do not yet have enough data to support an individualized approach to treatment. Clinical and biologic prognostic factors, degree of chemosensitivity as measured by FDG-PET, and histology should all likely have a role in directing patients along different treatment pathways, but prospective studies are needed to confirm this.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23006950      PMCID: PMC3968683          DOI: 10.1097/PPO.0b013e31826aeeb2

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  14 in total

1.  Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.

Authors:  Dennis D Weisenburger; Kerry J Savage; Nancy Lee Harris; Randy D Gascoyne; Elaine S Jaffe; Kenneth A MacLennan; Thomas Rüdiger; Stefano Pileri; Shigeo Nakamura; Bharat Nathwani; Elias Campo; Francoise Berger; Bertrand Coiffier; Won-Seog Kim; Harald Holte; Massimo Federico; Wing Y Au; Kensei Tobinai; James O Armitage; Julie M Vose
Journal:  Blood       Date:  2011-01-26       Impact factor: 22.113

2.  Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study.

Authors:  Andrea Gallamini; Caterina Stelitano; Roberta Calvi; Monica Bellei; Daniele Mattei; Umberto Vitolo; Fortunato Morabito; Maurizio Martelli; Ercole Brusamolino; Emilio Iannitto; Francesco Zaja; Sergio Cortelazzo; Luigi Rigacci; Liliana Devizzi; Giuseppe Todeschini; Gino Santini; Maura Brugiatelli; Massimo Federico
Journal:  Blood       Date:  2003-11-26       Impact factor: 22.113

3.  Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant.

Authors:  Esperanza B Papadopoulos; Miguel-Angel Perales; Jenna D Goldberg; Joanne F Chou; Steven Horwitz; Julie Teruya-Feldstein; Juliet N Barker; Farid Boulad; Hugo Castro-Malaspina; Sergio Giralt; Ann A Jakubowski; Guenther Koehne; Marcel R M van den Brink; James W Young; Zhigang Zhang
Journal:  Leuk Lymphoma       Date:  2012-01-31

4.  Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

Authors:  Michael Pfreundschuh; Joerg Schubert; Marita Ziepert; Rudolf Schmits; Martin Mohren; Eva Lengfelder; Marcel Reiser; Christina Nickenig; Michael Clemens; Norma Peter; Carsten Bokemeyer; Hartmut Eimermacher; Anthony Ho; Martin Hoffmann; Roland Mertelsmann; Lorenz Trümper; Leopold Balleisen; Ruediger Liersch; Bernd Metzner; Frank Hartmann; Bertram Glass; Viola Poeschel; Norbert Schmitz; Christian Ruebe; Alfred C Feller; Markus Loeffler
Journal:  Lancet Oncol       Date:  2008-01-15       Impact factor: 41.316

5.  Characterization of T-cell lymphomas by FDG PET/CT.

Authors:  John Feeney; Steven Horwitz; Mithat Gönen; Heiko Schöder
Journal:  AJR Am J Roentgenol       Date:  2010-08       Impact factor: 3.959

6.  Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.

Authors:  Norbert Schmitz; Lorenz Trümper; Marita Ziepert; Maike Nickelsen; Anthony D Ho; Bernd Metzner; Norma Peter; Markus Loeffler; Andreas Rosenwald; Michael Pfreundschuh
Journal:  Blood       Date:  2010-07-21       Impact factor: 22.113

7.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

Authors:  Julie Vose; James Armitage; Dennis Weisenburger
Journal:  J Clin Oncol       Date:  2008-07-14       Impact factor: 44.544

8.  Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification.

Authors:  K J Savage; M Chhanabhai; R D Gascoyne; J M Connors
Journal:  Ann Oncol       Date:  2004-10       Impact factor: 32.976

9.  Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.

Authors:  S Mercadal; J Briones; B Xicoy; C Pedro; L Escoda; C Estany; M Camós; L Colomo; I Espinosa; S Martínez; J M Ribera; R Martino; G Gutiérrez-García; E Montserrat; A López-Guillermo
Journal:  Ann Oncol       Date:  2008-02-25       Impact factor: 32.976

10.  Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study.

Authors:  Peter Reimer; Thomas Rüdiger; Eva Geissinger; Florian Weissinger; Christoph Nerl; Norbert Schmitz; Andreas Engert; Hermann Einsele; Hans Konrad Müller-Hermelink; Martin Wilhelm
Journal:  J Clin Oncol       Date:  2008-11-24       Impact factor: 44.544

View more
  1 in total

1.  Prognostic significance of [18F]fluorodeoxyglucose-positron emission tomography in peripheral T-cell lymphoma treated with stem cell transplantation: a retrospective analysis.

Authors:  Lauren Shea; Jingxia Liu; Amanda Cashen
Journal:  Leuk Lymphoma       Date:  2014-05-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.